Friday, 21 Feb 2020

You are here

Ustekinumab Effective in Behcet's Disease

A small prospective study has shown that ustekinumab is safe and effective in Behçet's disease (BD) with recurrent oral ulcers (OU).

This was a multicenter open label study of 30 BD patients with active OU that was resistant to colchicine. Ustekinumab (90 mg subcutaneously) was given at at inclusion, week 4, and then every 12 weeks. The primary efficacy endpoint was the proportion of patients with complete response (no oral ulcers) at week 12.

The median number of OU per patient significantly decreased from 2 [2-3] to 0 [0-1], p<0.0001] by week 12.

Complete response was achieved in 60.0% and 88.9% at week 12 and 24, respectively.

The median Behçet's syndrome activity score (in which higher scores indicating a more active disease) was significantly lower at week 12 and 24 compared to baseline [70 [50-70] vs. 17.5 [10-42.5] and 10 [8-11], respectively, p<0.0001].

After a median of 12 months of follow-up 87% of BD patients were still receiving ustekinumab treatment.

These pilot data suggest the IL-12/23 inhibitor, ustekinumab to be effective in treating refractory BD oral ulceration and merits further study. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Tofacitinib Effective in Refractory Still's Disease

Fourteen cases reported from mainland China suggest that tofacitinib (TOFA) may be effective in patients with refractory adult-onset Still’s disease (AOSD), further adding to a growing list of potential use of JAK inhibition in managing inflammatory, and now autoinflammatory, disease.

QD Clinic - Hepatitis B and Biologics

QD Clinic - Lessons from the clinic Active HBV infection (HGsAg+) on anti-viral therapy but needs a biologic - what should you use?

Biosimilars for Rheum Disease: Failure to Launch

The availability of biologic biosimilars has thus far had negligible impact on prescribing practices in the United States, in stark contrast to what has been observed in some European countries, researchers reported.

Best of 2019 - Is Methotrexate Necessary with Tofacitinib?

Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant worsening of disease activity, a researcher reported at EULAR 2019 in Madrid.

Best of 2019 - Ups and Downs with Abatacept

Two recent studies have examined the effect of starting abatacept upon the risk of serious hospitalized infections or cancer, showing divergent results from claims data analyses.